Aaron Perlitsh - Lifecore Biomedical Director Officer
| LFCR Stock | 6.39 0.04 0.63% |
Insider
Aaron Perlitsh is Director Officer of Lifecore Biomedical
| Address | 3515 Lyman Boulevard, Chaska, MN, United States, 55318 |
| Phone | 952 368 4300 |
| Web | https://www.lifecore.com |
Lifecore Biomedical Management Efficiency
The company has return on total asset (ROA) of (0.0467) % which means that it has lost $0.0467 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0452) %, meaning that it created substantial loss on money invested by shareholders. Lifecore Biomedical's management efficiency ratios could be used to measure how well Lifecore Biomedical manages its routine affairs as well as how well it operates its assets and liabilities. As of 05/05/2024, Return On Tangible Assets is likely to drop to -0.02. In addition to that, Return On Capital Employed is likely to drop to 0.01. At this time, Lifecore Biomedical's Non Currrent Assets Other are relatively stable compared to the past year. As of 05/05/2024, Other Current Assets is likely to grow to about 9 M, while Total Assets are likely to drop slightly above 246.8 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| Daniel OConnor | Eagle Pharmaceuticals | 44 | |
| Rinat Efrima | Im Cannabis Corp | 47 | |
| Patricio Munoz | Procaps Group SA | 51 | |
| Reiner Nowak | Eagle Pharmaceuticals | N/A | |
| Oren Shuster | Im Cannabis Corp | N/A | |
| Scott Gordon | Silver Spike Investment | 63 | |
| YatGai Au | Regencell Bioscience Holdings | 51 | |
| Advocate Harrosh | Im Cannabis Corp | N/A | |
| Melissa Angelini | Procaps Group SA | N/A | |
| Howard CFA | Im Cannabis Corp | 59 | |
| Michael Ruscetta | Im Cannabis Corp | 55 | |
| John Kimmet | Eagle Pharmaceuticals | N/A | |
| Wai Chung | Regencell Bioscience Holdings | 47 | |
| Shai Shemesh | Im Cannabis Corp | N/A | |
| Brian Cahill | Eagle Pharmaceuticals | 55 | |
| Michelle Chan | Regencell Bioscience Holdings | N/A | |
| Gregory Gentile | Silver Spike Investment | 48 | |
| Zhanchang Xin | Qilian International Holding | 57 | |
Management Performance
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.0467 |
Lifecore Biomedical Leadership Team
Elected by the shareholders, the Lifecore Biomedical's board of directors comprises two types of representatives: Lifecore Biomedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lifecore. The board's role is to monitor Lifecore Biomedical's management team and ensure that shareholders' interests are well served. Lifecore Biomedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lifecore Biomedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Darren Hieber, Senior Partnerships | ||
| Parker Javid, Vice President | ||
| James Hall, President CEO | ||
| Matt Augustson, Senior Technology | ||
| Kara Morley, Senior Resources | ||
| John Morberg, Executive CFO | ||
| Aaron Perlitsh, Director Officer | ||
| Steve Laninga, Vice Operations | ||
| Jackie Klecker, Executive GM | ||
| Kipling Thacker, VP Scientist | ||
| Albert Bolles, I Foods |
Lifecore Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lifecore Biomedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.0467 | ||||
| Profit Margin | (0.96) % | ||||
| Operating Margin | (0.08) % | ||||
| Current Valuation | 392.95 M | ||||
| Shares Outstanding | 30.55 M | ||||
| Shares Owned By Insiders | 4.53 % | ||||
| Shares Owned By Institutions | 74.66 % | ||||
| Number Of Shares Shorted | 1.89 M | ||||
| Price To Book | 1.57 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lifecore Biomedical. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lifecore Stock, please use our How to Invest in Lifecore Biomedical guide.Note that the Lifecore Biomedical information on this page should be used as a complementary analysis to other Lifecore Biomedical's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Complementary Tools for Lifecore Stock analysis
When running Lifecore Biomedical's price analysis, check to measure Lifecore Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lifecore Biomedical is operating at the current time. Most of Lifecore Biomedical's value examination focuses on studying past and present price action to predict the probability of Lifecore Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lifecore Biomedical's price. Additionally, you may evaluate how the addition of Lifecore Biomedical to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing |
Is Lifecore Biomedical's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lifecore Biomedical. If investors know Lifecore will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lifecore Biomedical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.14) | Revenue Per Share 3.447 | Quarterly Revenue Growth 0.208 | Return On Assets (0.05) | Return On Equity (1.05) |
The market value of Lifecore Biomedical is measured differently than its book value, which is the value of Lifecore that is recorded on the company's balance sheet. Investors also form their own opinion of Lifecore Biomedical's value that differs from its market value or its book value, called intrinsic value, which is Lifecore Biomedical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lifecore Biomedical's market value can be influenced by many factors that don't directly affect Lifecore Biomedical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lifecore Biomedical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lifecore Biomedical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lifecore Biomedical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.